Biotechnology Stocks Technical Review - Medivation, ACADIA Pharma, Regulus Therapeutics, and Vascular Biogenics

05 Jul, 2016, 08:35 ET from Chelmsford Park SA

NEW YORK, July 5, 2016 /PRNewswire/ --

On Friday, July 01, 2016, the NASDAQ Composite ended the trading session at 4,862.57, up 0.41%; the Dow Jones Industrial Average edged 0.11% higher, to finish at 17,949.37; and the S&P 500 closed at 2,102.95, up 0.19%. The gains were broad based as seven out of nine sectors ended the session in positive. has initiated coverage on the following equities: Medivation Inc. (NASDAQ: MDVN), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Regulus Therapeutics Inc. (NASDAQ: RGLS), and Vascular Biogenics Ltd (NASDAQ: VBLT). Learn more about these stocks by accessing their free trade alerts at:

On Friday, shares in San Francisco, California headquartered biopharmaceutical Company, Medivation Inc., ended the session 0.30% lower at $60.12 with a total volume of 1.61 million shares traded. Shares of the Company traded at a PE ratio of 42.04. The Company's shares have gained 36.08% in the previous three months and 7.30% in the past one year. The stock is trading 1.64% above its 50-day moving average and 32.07% above its 200-day moving average. Moreover, shares of Medivation have a Relative Strength Index (RSI) of 54.06. Sign up and read the free notes on MDVN at:

On Friday, shares in San Diego, California headquartered biopharmaceutical Company, ACADIA Pharmaceuticals Inc., ended the day 5.51% higher at $34.25 with a total volume of 1.89 million shares traded. The Company's shares have gained 13.94% in the previous three months. The stock is trading above its 50-day and 200-day moving averages by 1.22% and 11.57%, respectively. Furthermore, shares of ACADIA have an RSI of 50.50. The complimentary notes on ACAD can be downloaded in PDF format at:

San Diego, California headquartered biopharmaceutical Company, Regulus Therapeutics Inc.'s stock finished Friday's session 11.07% higher at $3.21 with a total volume of 1.79 million shares traded. The stock is trading below its 50-day moving average by 41.53%. Regulus Therapeutics' stock has an RSI of 30.57. Register for free on and access the latest research on RGLS at:

Or Yehuda, Israel headquartered clinical-stage biopharmaceutical Company, Vascular Biogenics Ltd's stock lost 4.56% to close the day at $4.40 with a total volume of 831,189 shares traded. The Company's shares have gained 16.09% in the last one month and 29.41% in the past three months. The stock is trading 15.56% above its 50-day moving average. Additionally, Vascular Biogenics' stock has an RSI of 53.00. Get free access to your trade alert on VBLT at:

Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email . Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA